SCHEMBL30361371

SCHEMBL30361371

CC(=O)c1cccc2c1C(=O)c1cccc(O)c1C2=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.68
MAPT P10636 8/20 0.60
ALDH1A1 P00352 6/20 0.60
TDP1 Q9NUW8 4/20 0.60
MAPK1 P28482 3/20 0.60
TSHR P16473 3/20 0.60
HPGD P15428 3/20 0.60
ALOX15 P16050 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
HSD17B10 Q99714 3/20 0.60
LMNA P02545 3/20 0.60
MAOB P27338 1/20 0.60
HTT P42858 1/20 0.60
STAT3 P40763 4/20 0.59
L3MBTL1 Q9Y468 1/20 0.51
FTO Q9C0B1 2/20 0.51
KMT2A Q03164 6/20 0.50
KDM4E B2RXH2 5/20 0.50
RECQL P46063 5/20 0.50
MEN1 O00255 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366938 1.00 MAOA (0.68) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL140425 1.00 MAOA (0.68) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL142033 0.95 ALDH1A1 (0.69) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL11147739 0.85 ALDH1A1 (0.70) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL8505898 0.85 ALDH1A1 (0.58) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL13880670 0.84 ELANE (0.50) MAOAMAPTALDH1A1TDP1MAPK1
SCHEMBL13881115 0.84 ELANE (0.50) MAOAMAPTALDH1A1TDP1MAPK1
Anthrarufin SCHEMBL187843 0.82 MAOA (1.00) MAOAMAPTALDH1A1TDP1MAPK1
Anthrarufin SCHEMBL29363946 0.82 MAOA (1.00) MAOAMAPTALDH1A1TDP1MAPK1
Anthrarufin SCHEMBL29874705 0.82 MAOA (1.00) MAOAMAPTALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114331-A1 CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY UNIV JOHNS HOPKINS (US) 2025-04-10 US disclosed
EP-4376960-A1 CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY The Johns Hopkins University (US) 2024-06-05 EP disclosed
WO-2023010141-A1 CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2023-02-02 WO disclosed